Minerva medica最新文献

Background: Circular RNAs (circRNAs) are significant modulatory molecules in the developing process of glioma. Our study will emphasize on exploring the function of circRNA Fanconi anemia group L protein (circFANCL) and the specific mechanism in glioma.

Methods: The quantitative real-time polymerase chain reaction (qRT-PCR) was implemented for detecting circFANCL, microRNA-337-3p (miR-337-3p) and high-mobility group box-1 (HMGB1). Cell proliferation analysis was assessed using cell counting kit-8 (CCK-8) and colony formation assays. Flow cytometry was applied to determine cell cycle and apoptosis. All protein detection was completed by western blot. Animal experiment was performed to investigate the role of circFANCL in vivo. Dual-luciferase reporter, RNA immunoprecipitation (RIP) and RNA pull-down assays were collectively conducted for analyzing the targeted combination.

Results: CircFANCL was signally increased in glioma tissues and cells, and the up-regulated circFANCL could predict poor prognosis in clinical glioma patients. Down-regulated circFANCL induced the proliferation inhibition, cell cycle arrest and apoptosis promotion of glioma cells in vitro, and inhibited tumor growth in vivo. Regarding the mechanism, circFANCL served as a sponge of miR-337-3p that was a tumor suppressor in glioma and circFANCL targeted miR-337-3p to regulate HMGB1 that was a target gene of miR-337-3p. Furthermore, HMGB1 down-regulation was responsible for the repression of glioma progression caused by knockdown of circFANCL.

Conclusions: Through the illustration of oncogenic function of circFANCL in glioma by the miR-337-3p/HMGB1 axis, we believed that circFANCL might be a great target in the early diagnosis and late treatment of glioma.

Background: This study aimed to investigate the expression and prognostic significance of topoisomeraseII (Topo-II) and c-erbB-2.

Methods: A total of 92 cases of patients with breast cancer who came to our hospital for treatment from November 2013 to January 2016 were included as the experimental group, and 90 healthy subjects who came to our hospital for physical examination during the same period were selected as the control group. ELISA was used to detect the expression levels of Topo-II and c-erbB-2 in serum of each group. The correlation among expression levels, degree of tumor differentiation and pathological types of Topo-II and c-erbB-2 in serum of patients with breast cancer were observed.

Results: The expression levels of Topo-II and c-erbB-2 in the experimental group were higher than those in the control group (P<0.05). The expression levels of Topo-II and c-erbB-2 in serum of patients with different stages increased with the clinical stages. The survival rate of patients with different expression levels of Topo-II and c-erbB-2 was compared, it was found that the survival rate of the low-expression group (80.49%) was significantly higher than that of the high-expression group (50.98%). The ROC curve was used to analyze Topo-II and c-erbB-2, the result showed that the sensitivity, specificity and AUC of Topo-II in the diagnosis of breast cancer was 72.22%, 94.56% and 0.8641, respectively. The sensitivity, specificity, and AUC of c-erbB-2 in the diagnosis of breast cancer were 94.45%, 66.30% and 0.8379, respectively.

Conclusions: In conclusion, Topo-II and c-erbB-2 are highly expressed in breast cancer and are closely related to breast cancer. Moreover, the detection of Topo-II and c-erbB-2 in serum can help diagnose gestational diabetes mellitus quickly and effectively.